153 related articles for article (PubMed ID: 15153311)
21. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations.
Scagnolari C; Bellomi F; Turriziani O; Bagnato F; Tomassini V; Lavolpe V; Ruggieri M; Bruschi F; Meucci G; Dicuonzo G; Antonelli G
J Interferon Cytokine Res; 2002 Feb; 22(2):207-13. PubMed ID: 11911803
[TBL] [Abstract][Full Text] [Related]
22. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.
Sørensen PS; Deisenhammer F; Duda P; Hohlfeld R; Myhr KM; Palace J; Polman C; Pozzilli C; Ross C;
Eur J Neurol; 2005 Nov; 12(11):817-27. PubMed ID: 16241970
[TBL] [Abstract][Full Text] [Related]
23. Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability.
Shokrollahi Barough M; Ashtari F; Sadat Akhavi M; Asghari N; Mosayebi G; Mirmohammadkhani M; Kokhaei N; Bahraminia F; Ajami A; Kokhaei P
Int Immunopharmacol; 2018 Sep; 62():109-113. PubMed ID: 29990690
[TBL] [Abstract][Full Text] [Related]
24. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
Hurwitz BJ
J Neurol Sci; 2008 Sep; 272(1-2):8-19. PubMed ID: 18620708
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
Petkau AJ; White RA; Ebers GC; Reder AT; Sibley WA; Lublin FD; Paty DW;
Mult Scler; 2004 Apr; 10(2):126-38. PubMed ID: 15124756
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P; Alm GV; Fredrikson S; Link H
Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
[TBL] [Abstract][Full Text] [Related]
27. [Flow cytometry model for the detection of neutralizing antibodies against of IFN-β].
Villa-Camacho JC; Vargas-Zambrano JC; González JM
Biomedica; 2012; 32(4):617-22. PubMed ID: 23715237
[TBL] [Abstract][Full Text] [Related]
28. Antibodies against interferon-beta in multiple sclerosis.
Aarskog NK; Marøy T; Myhr KM; Vedeler CA
J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
[TBL] [Abstract][Full Text] [Related]
29. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
[TBL] [Abstract][Full Text] [Related]
30. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
31. Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis.
Runkel L; De Dios C; Karpusas M; Baker D; Li Z; Zafari M; Betzenhauser M; Muldowney C; Miller S; Redlich PN; Grossberg SE; Whitty A; Hochman PS
J Interferon Cytokine Res; 2001 Nov; 21(11):931-41. PubMed ID: 11747625
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
33. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
[TBL] [Abstract][Full Text] [Related]
34. Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis.
Foley P; Reilly P; Coulson A; O'Riordan JI
J R Coll Physicians Edinb; 2010 Jun; 40(2):105-10. PubMed ID: 21125049
[TBL] [Abstract][Full Text] [Related]
35. The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study.
Paolicelli D; Manni A; Iaffaldano A; Di Lecce V; D'Onghia M; Iaffaldano P; Trojano M
Eur J Clin Pharmacol; 2016 Aug; 72(8):1025-9. PubMed ID: 27251359
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
37. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.
Bellomi F; Bramanti P; Trojano M; Scagnolari C; Muto A; Sessa E; La Volpe V; Russo P; Antonelli G
J Immunoassay Immunochem; 2009; 30(1):40-50. PubMed ID: 19117201
[TBL] [Abstract][Full Text] [Related]
38. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta.
Brickelmaier M; Hochman PS; Baciu R; Chao B; Cuervo JH; Whitty A
J Immunol Methods; 1999 Jul; 227(1-2):121-35. PubMed ID: 10485260
[TBL] [Abstract][Full Text] [Related]
39. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
[TBL] [Abstract][Full Text] [Related]
40. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
